Professor Lim, how can boosters protect others?
Where is the logic or indeed the ethics of the autumn booster programme?
Tag: children
AstraZeneca children’s trial breaches Helsinki
As a retired paediatrician, I was shocked to see the Oxford Vaccine Group advertising on Twitter for children aged 6-17 to join the latest Sars-CoV-2 vaccine trial[1]. In the two days it has taken me coposing this letter, I now see from tonight’s BBC news that the trial has already begun.
Com-COV-3 booster study for 12-15-year-olds
a letter to the senior investigator and the chair of the Research Ethics Committee 9th August 2022 Professor Matthew Snape, Chief Investigator Centre for Clinical Vaccinology and Tropical Medicine University of Oxford, Churchill Hospital, Old Road, Headington, Oxford, OX3 7LE Mr David Carpenter, Chairman, South Central – Berkshire Research Ethic Committee Bristol REC Centre, Temple […]
Full open letter to MHRA 17-05-2021
Supporting evidence re concerns surrounding COVID-19 vaccination in children Dr June Raine, CEO, Medicines & Healthcare devices Regulatory Authority, cc: Professor Lim, Chairman, JCVI Covid-19 vaccines committee cc: Professor Chris Whitty, CMO, Co-chair of SAGE cc: Sir Patrick Vallence, Chief Scientific Officer, Co-chair of SAGE Dear Dr Raine, We wish to notify you of our […]
Open Letter to MHRA on vaccines for 0-5s
Open letter to the MHRA re Moderna application for 0-5s. Will Dame June follow this baby’s view on the precautionary principle? One can live in hopes!
Latest Open Letter to our Latest Prime Minister
Yet another open letter to the Prime Minister on the lack of safety of Covid-19 vaccines for children
Letter from ONS presented in the High Court in London 12-01-2021
By email only 12 January 2022 DX 123243, Westminster 12 www.gov.uk/gld Your ref: SJ/JRMHRA22101 Our ref: Z2112698/BDH/HOI7 Dear Sirs Re: Application for non-party disclosure in R (on the application of (1) AB and (2) CD, children by their mother and litigation friend, EF) v The Office for National Statistics CO/3001/2021 We write in response to […]
